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Brain natriuretic peptide is related to diastolic
dysfunction whereas urinary albumin excretion
rate is related to left ventricular mass in
asymptomatic type 2 diabetes patients
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Abstract
Background: The aims of this study were to estimate the prevalence of left ventricular systolic (LVSD) and diastolic
(LVDD) dysfunction, and to test if BNP and urinary albumin excretion rate (AER) are related to LVSD, LVD and left
ventricular mass (LVM) in asymptomatic type 2 diabetes patients.
Methods: Presence of LVSD, LVDD and LVM, determined with echocardiography, was related to levels of BNP and
AER in 153 consecutive asymptomatic patients with type 2 diabetes.
Results: LVSD was present in 6.1% of patients whereas 49% (29% mild, 19% moderate and 0.7% severe) had LVDD
and 9.4% had left ventricular hypertrophy. Increasing age (P < 0.0001) was the only independent variable related to
mild LVDD whereas increasing BNP (P = 0.01), systolic blood pressure (P = 0.01), age (P = 0.003) and female
gender (P = 0.04) were independent determinants of moderate to severe LVDD. AER (P = 0.003), age (P = 0.01)
and male gender (P = 0.006) were directly and independently related to LVM.
Conclusion: About half of asymptomatic type 2 diabetes patients have LVDD. Of those, more than one third
display moderate LVDD pattern paralleled by increases in BNP, suggesting markedly increased risk of heart failure,
especially in females, whereas AER and male sex are related to LVM.
Background
The steadily increasing prevalence of diabetes constitu-
tes a major health problem. By the year 2025, the preva-
lence of diabetes is estimated to be as high as 5.4% [1].
This is to be compared with reports from Swedish cor-
onary care units, which suggest that as many as 66% of
the patients admitted in fact have previously undiag-
nosed diabetes or pre-diabetes (impaired glucose toler-
ance) [2]. Cardiovascular disease (CVD) is also the
major contributor to mortality in the diabetic population
[3]. Screening for micro-vascular complications has been
routine for decades, but no similar practice for early
detection and treatment of cardiac complications has
been conducted. This is especially notable, since treat-
ment at different stages of heart dysfunction, even
asymptomatic, has proved to reduce cardiovascular com-
plications [4,5]. It is also well known that microalbumi-
nuria is a powerful predictor of CVD, especially in
patients with type 2 diabetes [6], and this subset group
would probably benefit even more from a cardiac
screening. Routine echocardiography (echo) assessment
would be considered optimal for such conduct, but is
not always possible due to lack of accessibility. The
measurement of the natriuretic peptides has been sug-
gested as a tool to identify patients who could benefit
from further risk evaluation by echo for the early detec-
tion and treatment of cardiac abnormalities [7]. We
have previously reported that, in a material of patients
with type 2 diabetes without known cardiovascular dis-
ease, over 60% of the patients had N-terminal proBNP
values above accepted cut off limits for the detection of
cardiac abnormalities [8]. However, no echo examina-
tions were conducted in that study and it is unknown
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whether clinically easy-to-use markers like BNP and
microalbuminuria can be used to identify type 2 dia-
betes patients with early signs of heart disease such as
left ventricular dysfunction (LVD) and left ventricular
hypertrophy (LVH). Therefore, in this study we set out
to estimate the prevalence of left ventricular systolic
dysfunction (LVSD), left ventricular diastolic dysfunction
(LVDD) and LVH as measured by echo in a population
of patients with type 2 diabetes and no history or symp-
toms of CVD, and further, in the same population, to
test if BNP and urinary albumin excretion rate (AER)
are related to LVSD, LVDD and left ventricular mass
index (LVM) independently of each other, age, sex, dia-
betes duration, systolic blood pressure, metabolic con-
trol, lipid levels, body mass index and kidney function.
Materials and methods
Patients and protocol
The study population consisted of 153 consecutive
patients with type 2 diabetes with no history of symp-
toms of cardiovascular disease being part of a screening
program for heart disease in type 2 diabetes patients
without known macrovascular disease in Malmö, Swe-
den. This is a joint venture between the primary care in
Malmö and the departments of cardiology and endocri-
nology at Malmö University Hospital. Patients with
newly diagnosed diabetes without known cardiovascular
disease are examined thoroughly, (e.g. with echo and a
broad range of cardiovascular risk factors) and interven-
tions are executed on the basis of the examination
results. The patients were admitted consecutively and
the mean age was 55 ± 11 years, though our aim was to
examine newly diagnosed diabetes patients, the duration
of diabetes was found to be longer than expected, 6.3 ±
7.2 years and 46% of the patients had hypertension.
Clinical and biochemical characteristics are shown in
table 1 and echo variables are shown in table 2. The
local ethics committee of Lund University approved the
study, which was conducted according to the principles
of the Declaration of Helsinki and thus all participating
patients gave their written informed consent and proce-
dures involving patients were performed according to
institutional guidelines.
Blood pressure
Blood pressure was measured three times in the right
arm in seated position after 10 min rest and the mean
value of the three recordings was calculated. Korotkoff
sounds corresponding to ‘phase I’ was used to define the
systolic and ‘phase V’ the diastolic blood pressure.
Hypertension was defined as systolic or diastolic blood
pressure of 140/90 mmHg or greater or use of antihy-
pertensive medication.
Diabetes
Diabetes mellitus was defined as a fasting whole blood
glucose level greater than 109 mg/dL (6.0 mmol/L) or
use of antidiabetic medication.
Echocardiography
All patients underwent complete 2-dimensional echocar-
diography and Doppler studies in the left lateral decubi-
tus position from multipline windows, using
commercially available equipment (SONOS 7500, Philips
Medical Systems, Andover, Massachusetts) with a
phased array transducer of 2.5 MHz, and with a system
equipped with Doppler tissue imaging technology.
Pulsed Doppler tissue imaging is a new echo method
based on the display of low frequency, high amplitude
Doppler signals originated in the myocardium. A
detailed concept and technical aspects of this approach
have previously been published [9,10]. All images were
recorded during two cardiac cycles and were stored digi-
tally and post processed.
In addition to pulsed Doppler tissue imaging, conven-
tional echo was performed, including M-mode, 2-dimen-
sional, pulsed and colour Doppler echocardiography.
Right ventricular and left ventricular diameters, left and
right atrium diameters, septal and posterior wall thick-
ness were measured according to the recommendations
of the American Society of Echocardiography, and left
ventricular ejection fractions were calculated using the
biplane Simpsons [11]. The severity of valve regurgita-
tions and stenoses was defined according to the clinical
practice guidelines at Malmö University Hospital and in
agreement with ACC/AHA guidelines [12].
The assessment of the severity of the valvular stenoses
and regurgitations was performed using a combination
of qualitative and quantitative analysis based on echo-
cardiographic spectral and colour Doppler
measurements.
The assessment of diastolic heart function was defined
according to European Society of Cardiology [13] and
LVDD was divided into mild (relaxation impairment),
moderate (pseudonormalisation pattern) and severe
(restrictive pattern). Diagnostic evidence of LVDD was
obtained among other by tissue Doppler (E/é), blood
flow Doppler of mitral valve, pulmonary veins and echo
measures of LVM index (figure 1). LVSD was defined as
ejection fraction below 55%. LVH was defined as LVM
of at least 110 g/m2 in women and 125 g/m2 in men.
LV-mass (LVM) was calculated according to the for-
mula:
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Table 1 Clinical characteristics of the study population.
Variable Patients without LVDD n = 78
Mean
Patients with LVDD n = 75 Mean p value
Age 50 ± 12 59 ± 10 < 0.001
Sex (% male) 51 49 0,1
SBP (mmHg) 134 ± 16 141 ± 16 0.006
DBP (mmHg) 79 ± 9.0 80 ± 8.0 0.6
HT (%) 36 58 0.009
Crea ((μmol/L) 73 ± 19 81 ± 42 0.1
GFR (ml/min) 137 ± 52 116 ± 41 0.005
Dyslipidemia (%) 51 49 0,3
lnAER ( g/min) 2.1 ± 1.3 2.3 ± 1.7 0.4
lnBNP (pmol/L) 1.1 ± 1.0 1.6 ± 1.1 0.01
HbA1c (%) 7.0 ± 2.0 6.5 ± 1.4 0.04
fP-glucose (mmol/L) 9.3 ± 3.8 8.9 ± 3.0 0.5
DM duration (years) 4,7 ± 6,6 8.0 ± 7.6 0.005
Smoking (%) 15 9 0.2
BMI (kg/m2) 30 ± 6.1 31 ± 5.2 0.3
TG (mmol/L) 1.8 ± 1.1 1.8 ± 1.0 1.0
HDL (mmol/L) 1.1 ± 0.3 1.2 ± 0.4 0.3
LDL (mmol/L) 2.9 ± 0.8 2.7 ± 1.0 0.2
BSA (m2) 2.0 ± 0.24 2.0 ± 0.20 0.5
Data are expressed as mean ± SD. SBP; systolic blood pressure, DBP; diastolic blood pressure, HT; hypertension, Crea; creatinine, GFR, glomerular filtration rate,
AER, urinary albumin excretion rate, BNP, brain natriuretic peptide, f; fasting, DM; diabetes mellitus, BMI; body mass index, TG; triglycerides, HDL; high density
lipoproteins, LDL; low density lipoproteins, BSA; body surface area, ln; natural logarithm.
Table 2 Echocardiographic parameters
Variable Patients without LVDD n = 78
Mean
Patients with LVDD n = 75 Mean p value
EF (%) 60 ± 6.2 56 ± 10 0.03
E (cm/s) 78 ± 15 79 ± 18 0.8
A (cm/s) 68 ± 15 97 ± 57 0.001
Edt (s) 0.2 ± 0.06 0.2 ± 0.05 0.2
Pulmonary vein flow 1.4 ± 0.7 1.2 ± 0.6 0.2
RA diameter (mm/m2) 24 ± 4,5 25 ± 4.4 0.3
IVSDd (mm/m2) 5.8 ± 1.0 6.0 ± 0.8 0.3
LVIDd (mm/m2) 24 ± 2.5 24 ± 2.6 0.5
RVIDd (mm/m2) 14 ± 1.9 15 ± 2.2 0.2
PWDd (mm/m2) 4.6 ± 0.7 4.5 ± 0.7 0.6
PSVsept (cm/s) 9.2 ± 6.8 7.7 ± 1.6 0.1
Èsept (cm/s) 10 ± 6.7 6.7 ± 1.8 0.001
Ásept (cm/s) 9.3 ± 2.0 10 ± 2.6 0.06
PSVlat (cm/s) 8.9 ± 2.4 8.4 ± 2.0 0.2
Élat (cm/s) 11 ± 3.2 9.1 ± 2.3 < 0.001
Álat (cm/s) 10 ± 3.6 11 ± 3.1 0.2
LA diameter (mm/m2) 20 ± 2.3 20 ± 1.9 0.7
LVM (g/m2) 87 ± 22 88 ± 25 0.9
Data are expressed as mean ± SD. BSA; body surface area, EF; ejection fraction, E; peak early mitral valve velocity, A; peak late atrial mitral valve velocity, Edt;
deceleration time, LA; left atrium, RA; right atrium, IVSDd; interventricular systolic diameter diastole, LVIDd; left ventricular inner diameter diastole, RVIDd; right
ventricular inner diameter diastole, PWDd; posterior wall diameter diastole, PSVsep; peak systolic myocardial velocity at mitral annulus in septal wall, Ésept; early
diastolic tissue velocity at mitral annulus in septal wall, Ásept; late diastolic tissue velocity at mitral annulus in septal wall, PSVlat; peak systolic myocardial
velocity at mitral annulus in lateral wall, Élat; early diastolic tissue velocity at mitral annulus in lateral wall, Álat; late diastolic tissue velocity at mitral annulus in
lateral wall, LVM; left ventricular mass.
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PWTd: posterior wall thickness in diastole, SWTd:
septal wall thickness in diastole, LVIDd: left ventricular
inner diameter in diastole.
Biochemical assays
At the time of echocardiography, venous blood was
sampled and transferred into pre-chilled EDTA vacutai-
ners for analysis of BNP. Immediately after sampling the
tubes were placed on ice and centrifuged at 4°C before
plasma aliquots were frozen at -70°C for later analysis.
Plasma BNP was measured with the Triage BNP Assay
from Biosite Inc, San Diego, CA, using the UniCel™
immunoassay System from Beckman Coulter Inc, Brea,
Ca. Lower limit of detection is 1 pg/mL (0.29 pmol/L).
Within assay CVs are 3.1% and 1.0% at the levels of
40.8 and 1343 pg/mL. Corresponding between assay
CVs are 4.5 and 6.6%. HbA1c was analysed using the
Variant II chromatographic method from Bio-Rad (CA,
USA) with a coefficient of variance (CV) of 3.0% at
HbA1c 4.4-8.8%. The urinary albumin concentration
was measured in over-night urine collections (12 hours)
using an immunoturbimetric method (BeckmanCoulter,
Beckman Instruments, CA, USA). Glomerular filtration
rate (GFR) was calculated from the the Cockcroft-Gault
formula; GFR (mL/min/1.73 m2) = ((140-age (years)) ×
body weight (kg))/(0.81 × Screat (mmol/l)) × (1:73 (m2)/
BSA (m2))(×0.85 if female).
Figure 1 Practical approach to grade diastolic dysfunction.
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Statistics
Normally distributed data are presented as means ± SD
whereas data with skewed distributions are presented as
medians and inter quartile ranges (IQR). Univariate dif-
ferences in continuous variables was tested using Stu-
dent’s t-test with skewed variables being ln-transformed
before analysis whereas chi-2 test was used to for differ-
ences in dichotomised variables. Correlation coefficients
were calculated using Pearson’s or Spearman’s correla-
tion analysis depending on normality of the residuals.
Linear regressions, with skewed variables were ln trans-
formed, and logistic regressions were used to test for
multivariate relationships with continuous and dichoto-
mous variables, respectively. All baseline variables (table
1) were entered into the multivariate models and were
retained in the model if P < 0.05 using backward elimi-
nation. Two-sided tests were used and P < 0.05 was
considered statistically significant throughout.
Results
Clinical and biochemical characteristics are shown in
table 1 and echo variables are shown in table 2. The
mean blood pressure constitutes a mixture of blood
pressure under treatment and untreated patients. On
average patients had a LVM below the applied limits for
LVH and 9.4% fulfilled the criteria for LVH. LVSD was
only present in 6,1% of the subjects whereas 49% of the
patients had echo signs of LVDD (29% mild, 19% mod-
erate and 0.7% severe).
BNP and AER in relation to LVM
In a univariate analyses lnAER was significantly corre-
lated (r = 0.34, P < 0.0001) and lnBNP showed a strong
tendency without reaching the level of statistical signifi-
cance (r = 0.17, P = 0.06) with LVM. However, in a
multivariate linear regression model including all base-
line covariates (table 1), only AER (unstandardized b
coefficient (b) and (±SD) = 4.3 ± 1.4, P = 0.003), age (b
= 0.48 ± 0.18, P = 0.01) and male gender (b = -13 ± 4.7,
P = 0.006) remained independently related to LVM.
Correlations to diastolic dysfunction
When comparing patients with and without mild diasto-
lic dysfunction (patients with moderate to severe LVDD
excluded), we found no difference in lnBNP or lnAER,
although there was a tendency towards higher lnBNP in
patients with mild LVDD (1.3 ± 0.79 vs 0.98 ± 0.85, P =
0.09). Patients with mild LVDD were found to be signif-
icantly older (59 ± 7.6 vs 49 ± 11 years; P < 0.0001),
have longer duration of diabetes (8.0 ± 8.0 vs. 4.6 ± 6.7
years; P = 0.02) and lower GFR (99 ± 27 vs 120 ± 33
ml/min/1.73 m2; P = 0.002). However, in a multivariate
logistic regression analysis, increasing age (P < 0.0001)
remained the only independent variable related to mild
LVDD.
Patients with moderate to severe LVDD had signifi-
cantly higher lnBNP (2.1 ± 1.4 vs 0.98 ± 0.85 pmol/L; P
< 0.0001) (figure 2) as compared to patients with normal
left ventricular dysfunction, whereas there was no differ-
ence in AER (2.6 ± 2.0 vs 2.0 ± 1.3 μg/min; P = 0.12).
In addition, they were significantly older (59 ± 13 vs 49
± 11 years; P < 0.0001), had longer duration of diabetes
(7.9 ± 7.2 vs 4.6 ± 6.7 years, P = 0.03), higher systolic
blood pressure (146 ± 18 vs 133 ± 16 mmHg; P =
0.001) and lower GFR (97.0 ± 32.7 vs 118 ± 33.3 ml/
min/1.73 m2 P < 0.005). In multivariate logistic regres-
sion analysis the OR for moderate to severe LVDD per
one unit increase in the respective variable was calcu-
lated. BNP, systolic blood pressure (SBP), age and
female gender were all independently influencing the
risk of moderate to severe LVDD per one unit increase
in the respective variable. The multivariate adjusted OR
(95% CI) for moderate to severe LVDD was 1.14 (1.03-
1.25) for BNP, 1.05 (1.01-1.09) for SBP, 1.10 (1.03-1.16)
for age and 3.61 (1.03-12.7) for female gender. Further-
more, a ROC analysis was performed to evaluate the
diagnostic performance for BNP as a discriminator for
the detection of moderate to severe LVDD, and was
expressed as a calculation of area under curve (AUC)
level. Regarding the ability to diagnose if moderate to
severe LVDD was present, ROC analysis showed a sig-
nificant diagnostic performance for BNP (AUC = 0.74
(0.62-0.85), p < 0.0001) for the detection of moderate to
severe LVDD.
Discussion
Although BNP is a well-established screening tool for
LVSD and AER is routinely used for cardiovascular risk
estimation, it is not known whether these two biomar-
kers are clinically useful for screening of LVDD and
LVH in patients with type 2 diabetes with no prior
CVD. The present study has demonstrated that echocar-
diographic screening of asymptomatic diabetic subjects
without known CVD may identify significant numbers
of patients with asymptomatic LVDD and LVH. We also
show that BNP is independently related to moderate to
severe LVDD whereas AER is directly and independently
related to LVM.
Prevalence of subclinical heart disease in a diabetic
population
Our data shows a prevalence of 49% of LVDD (29%
mild, 19% moderate and 0.7% severe LVDD) in presum-
ably heart healthy asymptomatic patients with type 2
diabetes. These findings are well in line with earlier stu-
dies i.e. data from Poirier et al were 46 men with type 2
diabetes who were aged 38-67 years; without evidence
of diabetic complications, hypertension, coronary artery
disease, congestive heart failure, or thyroid or overt
renal disease; and with a maximal treadmill exercise test
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showing no ischemia, were studied. Twenty-eight of the
subjects (60%) were found to have LVDD, of whom 13
(28%) had moderate LVDD and 15 (32%) had mild
LVDD [14].
In our study, LVH was observed in only 9.4% of the
patients. Fang et al. reported that in asymptomatic
patients with diabetes mellitus without known cardiac
disease, which underwent clinical evaluation and
detailed echo assessment, approximately 20% fulfilled
the criteria for LVH.
It has recently been published data by Srivastava and
coworkers, showing a high prevalence of LVDD and
LVH (59% and 70% respectively) [15] in patients with
type 2 diabetes. As in our study, the prevalence of
LVSD was fairly low (16%). The prevalence of LVH
reported in that study is higher compared to our find-
ings (70% v s 9.4%). However in that study population,
19% had known macrovascular disease. Interestingly,
increasing age, diabetes duration and BMI were the only
independent predictors of cardiac abnormalities. No dif-
ferences regarding cardiac abnormalities between male
and females were reported for [15].
BNP and correlations to echo abnormalities
We have previously reported that patients with type 2
diabetes have higher levels of BNP compared to patients
without diabetes, indicating a high prevalence of asymp-
tomatic heart disease [8]. However, since no echo regis-
trations were done in this study [8], no information
regarding what underlying heart disease an elevated
BNP value would represent could be obtained. For
screening purposes BNP have been proven useful to rule
out heart failure (HF) with impaired LVSD [16]. BNP
have also been shown useful for the assessment of
LVDD at the population level [17] whereas its role for
LVDD screening has not previously been investigated in
type 2 diabetes patients with no prior CVD. We found
that BNP is an independent determinant of moderate to
severe LVDD. This is illustrated in figure 1 were BNP
appears as good discriminator for the detection of mod-
erate to severe LVDD in patients with type 2 diabetes.
Henceforth, plasma BNP levels above 1.5 pmol/l indi-
cates coexisting moderate diastolic dysfunction and
further examination with echo would be warranted to
further confirm this.
On the other hand, we did not found any significant
relationship between BNP and mild LVDD or LVM,
respectively. In accordance with the latter finding,
screening with BNP for the presence of LVH in hyper-
tensive patients has showed limited value [18].
AER and correlations to echocardiographical
abnormalities
Whereas BNP was not associated to LVH, our data sug-
gests that AER could be useful as a marker for LVH, as
estimated by LVM, given its independent and direct
relationship with LVM. An independent relationship
between LVM and AER has not been reported earlier in
type 2 diabetes and further emphasizes increased CVD
risk and need of antihypertensive treatment in type 2
diabetes patients with microalbuminuria. Thus, this
finding might serve as an explanatory model for the
known risk of CVD in patients with microalbuminuria
[6], since LVH is well associated with increased morbid-
ity and mortality in CVD [19].
Male gender and left ventricular hypertrophy
The correlation between male gender and LVM is in
line with the study by Concardy et al in 2004, in which
it was shown that the LVH estimation without sex-spe-
cific criteria underestimated the prevalence of LVH in
women and overestimates it in men, and even if sex
specific definitions for LVH was used male gender still
contributed to the prevalence of LVH in this study [20].
Furthermore, an independent influence of increasing
LVM and age were reported by Concardy et al and this
influence was only seen in the male population of the
study. Even if the patients studied by Concardy et al
were hypertensive peers with higher prevalence of LVH
(52.2%) compared to our diabetic population with a
LVH prevalence of 9.4%, the data are in concordance
with our findings and might represent a gender specific
mechanism for the development of LVH. This is further
supported by data from the Tromsö study in which
male sex was found to be an independent predictor of
LVH in a multivariate logistic regression analysis [21].
Female gender and diastolic dysfunction
Another interesting finding from the present study is
the increased risk for moderate LVDD for female study
subjects. The mechanism behind such a gender
Figure 2 Distribution of BNP values in the patient with normal
and moderate-severe diastolic dysfunction. P for difference
between groups < 0.001.
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dependent pathophysiology is unclear. However, the
results of the Framingham study revealed that between
the ages of 45 and 75, men and women with diabetes
had a two-fold- and five-fold increase in risk of develop-
ing heart failure, respectively, compared to patients
without diabetes. This risk persisted even after consider-
ing age, blood pressure, cholesterol, weight, and history
of coronary artery disease [22]. Further studies are
indeed warranted regarding this matter.
Screening for cardiac abnormalities in asymptomatic
patients with type 2 diabetes
In our study almost half of the study population had
LVDD and nearly ten percent had LVH. The treatment
of LVH and LVSD is well established and has proved to
reduce cardiovascular complication [4,5]. However, the
importance of diagnosing LVDD has just been acknowl-
edged and the presence of LVDD provide essential prog-
nostic information [23]. Although the most effective
treatment of LVDD in patients with type 2 diabetes is
unknown, it is well established that an effective aggres-
sive multifactorial approach indeed reduces micro- and
macrovascular complications [24]. Furthermore, recently
published data suggests cardiovascular benefits of more
aggressive blood pressure lowering therapy amongst
patients with type 2 diabetes [25]. Henceforth, an early
detection of cardiac abnormalities such as LVSD, LVDD
and LVH is crucial and might guide the clinicians to
more intense risk factor management and aggressive
pharmacological treatment of this high-risk population.
Screening with echo would be considered optimal for
such a conduct, but is not always eligible due to lack of
accessibility and high cost. Our data suggest that the
measurement of BNP and AER might be used as a
screening tool in order to select patients for further
work up with echo. However, the study sample size of a
total of 153 subjects, which indeed is a respectable num-
ber for an echocardiographic study, might not be large
enough to be definitive or inform clinical practice and
therefore the results from the multivariate analysis
needs to be confirmed in larger study samples.
Conclusion
In conclusion, this study has demonstrated that echo
screening of asymptomatic diabetic subjects with appar-
ently normal cardiac function may identify significant
numbers of patients with asymptomatic LVDD and LVH.
Almost half of the presumably heart healthy population
had LVDD. BNP discriminates patients at high risk for
moderate to severe LVDD, and might therefore be used
as screening tool in order to capture patients eligible for
further risk stratification with echo. LVH was associated
with male gender and AER, whereas moderate LVDD
was associated with female gender and BNP, implying
gender specific mechanism in the development of CVD.
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